CBER’s Blood Safety Team Blood Products Advisory Committee 01 May 2008 Jonathan C. Goldsmith, MD Office of Blood Research and Review.

Slides:



Advertisements
Similar presentations
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Advertisements

Regulatory Challenges in the Cell Preparation Facility Adrian Gee Center for Cell & Gene Therapy Regulatory Challenges in the Cell Preparation Facility.
Development of Guidance Documents Jennifer Scharpf, M. P. H
Public Workshop: Quarantine Release Errors in Blood Establishments September 13, 2011 QREs Past, Present and Future Sheryl A. Kochman Deputy Director Division.
Susan N. Hocevar, MD Medical Officer Office of Blood, Organ, and Other Tissue Safety Division of Healthcare Quality and Promotion Investigation Framework.
The Safety of the Blood Supply
Introduction to Regulation
An Overview of Mission-related Research Office of Blood Research and Review C.D. Atreya, Ph.D. Associate Director for Research OBRR, CBER BPAC, Dec
CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.
Transfusion Transmission of HIV 1. Past & Current Risk Estimates of Transfusion-Transmitted HIV Infection 2. Layers of Safety in Protection of the Blood.
Treviso, 21 October Karin Magnussen. Donors outside the Blood Bank /Centre Donors in the Blood Bank /Centre Blood products Blood Group serology The Patients.
Current standards, donor safety, and blood supply
FDA Basics: Tissue Safety
CBER Cooperative Manufacturing Arrangements (Contractors) Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
Good Manufacturing Practices for Blood Establishments
Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.
CBER Blood Establishment Registration and Product Listing Jan O’Brien Blood Registration Coordinator DBA, OBRR, CBER September 15, 2009.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
CBER U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
European Health Forum 2003Reinhart Waneck1 Safety and Quality of Human Blood Products and Human Blood Derivatives in an Enlarged European Union The experience.
FDA Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components.
Critical Path Opportunities for Biologics Products Jesse L. Goodman, M.D. M.P.H. Director Kathryn M. Carbone, M.D. Associate Director for Research Center.
FDA and American Red Cross Blood Supply Safety & Protection Geoff Withnell, CQE, CQA, CQMgr System Design Engineer American Red Cross.
FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.
Ensuring Product Quality in Gene Transfer Clinical Trials
IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.
NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.
CBER 1 Establishment Submissions Rosia E. Nesbitt, BS, SBB(ASCP), CQA(ASQ) Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.
Approach and Key Components. The Goal of Cities for Life: To help community groups and primary care providers create an environment that facilitates and.
Basma Y. Kentab MSc.. 1. Define ambulatory care 2. Describe the value of ambulatory care practices 3. Explore pharmacy services in some ambulatory care.
Dual Use Research of Concern Boston University and Boston Medical Center.
Challenges in evaluating and changing donor criteria Dr. Mindy Goldman Transfusion Medicine Residents April 30, 2008.
The ‘Achilles’ project: a WHO initiative to support quality in the manufacturing of plasma for fractionation Dr Ana Padilla, Blood Products & related Biologicals.
1 Donor’s Written Statement of Understanding Beth H. Shaz, MD Chief Medical Officer New York Blood Center Clinical Associate Professor Emory University.
Current Considerations on Plasma for Further Manufacturing Obtained from Whole Blood Donors Alan E. Williams, Ph.D. Associate Director for Regulatory Affairs,
Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.
Regulatory Big Brother of Biotechnology. Role of FDA FDA was designed to promote and protect the public’s health Food and Drug Cosmetic Act first passed.
Apheresis Blood Components
COMPLIANCE ACTIONS FDA Regulation & Licensure of Whole Blood & Blood Components, Including Source Plasma September 15-16, 2009 Helen Cowley Office of Compliance.
REGULATIONS FOR BLOOD and BLOOD PRODUCTS JILL HOAG BS, SBB(ASCP) CQA(ASQ) AABB STAFF LEAD ASSESSOR 1.
Update on FDA Workshop on Immune Globulins for Primary Immune Deficiency Diseases: Antibody Specificity, Potency and Testing Blood Products Advisory Committee.
12 th Annual FDA & the Changing Paradigm for Blood Regulation – 01/16/2009 – Las Vegas, NV – Gilliam B. Conley 1 FDA perspective on “Where are we? Where.
FDA EID Workshop: Day 2 Organs, Tissues and Cells Melissa A. Greenwald, MD Blood Products Advisory Committee 26 July 2010 Gaithersburg, MD.
Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.
Expectations for Facilities & cGMPs Biological Response Modifiers Advisory Committee Meeting October 9, 2003 Nicholas Obiri, Ph.D. CBER.
Ad Hoc Disease Transmission Advisory Committee Fall 2014.
Dispensary and Administration Site Information Presentation.
OBRR Response to BPAC Recommendations on the Office Research Program Office Site Visit: July 22, 2005 BPAC Recommendations: February 10, 2006 C.D. Atreya,
Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies;
CBER Common Problems on Source Plasma Inspections Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.
FDA Perspective on the PASSPORT Study FDA Perspective on the PASSPORT Study Salim A. Haddad, M.D. Laboratory of Cellular Hematology Division of Hematology.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
Deferral of Blood and Plasma Donors for History of Transfusion in BSE Countries of Europe Alan E. Williams, Ph.D. Director, Division of Blood Applications.
WHO Regional Workshop on Good Manufacturing Practices for Blood Establishments Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
FDA Risk Management Strategy for Potential Exposure to vCJD from Plasma Derivatives TSE Advisory Committee December 15, 2006 Dorothy Scott, M.D. OBRR/CBER.
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.
CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.
The Regulation on Cell Therapy Products in Japan
Presented by Karen Dosanjh Quality Director Blood Systems
American Society for Quality Region 5 Quality Conference
Combination products The paradigm shift
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH
Patient Involvement in the Development and Safe Use of
FDA Sentinel Initiative
Regulatory Perspective of the Use of EHRs in RCTs
Presentation transcript:

CBER’s Blood Safety Team Blood Products Advisory Committee 01 May 2008 Jonathan C. Goldsmith, MD Office of Blood Research and Review

The CBER Blood Safety Team Need for a Blood Safety Team Legal framework for Blood Regulation The Layers of Blood Safety The Blood Safety Team –Goals and Objectives –Organizational Structure Activities of the Blood Safety Team Long term challenges

Basis for the BST: Annual U.S. Blood Donation and Utilization 8 million unpaid volunteers donate approximately 15 million units of Whole Blood 4.5 million patients receive about 29 million units of blood components ~2.4 million units of “recovered plasma” from Whole Blood donation are sold for further manufacturing, including fractionation One million paid apheresis donors provide an additional ~10 million liters of Source Plasma for fractionation

Basis for the BST: Scope of FDA-Regulated Blood and Related Device and Drug Establishments Blood Collection Centers - ~1,300 –Community Based (90% of collections) –Hospital Based (8% of collections) –Military (2% of collections) Hospital Transfusion Services - ~5,000 –Vast majority only cross match and dispense Device Manufacturers - ~400 –Test Kits, Blood Grouping Reagents –Apheresis machines, blood warmers, etc. Drug Manufacturers (e.g. anticoagulants) - ~30

Basis for the BST: Scope of FDA-Regulated Blood and Related Device and Drug Establishments Plasmapheresis Centers - ~300 Plasma Derivative Manufacturers - ~20 Products –Coagulation Factors –Immune Globulins –Antitoxins –Albumin –Alpha-1-Proteinase Inhibitor –AT III

Legal Framework for FDA Regulation - I U.S. Blood and plasma are collected, processed and distributed by private industry regulated by the FDA under two national laws Public Health Service (PHS) ACT (42 USC 202 et. seq.) Section 351 (biologics regulation*) Section 361 (communicable disease control) *Licensed biological products concurrently are drugs or devices under the FD&C Act

Legal Framework for FDA Regulation - II Federal Food, Drug and Cosmetic (FD&C) Act (21 USC 302 et. seq.) Addresses drugs and medical devices FDA Amendment Act of 2007 Blood organizations also comply with State laws and voluntary standards (e.g. AABB, PPTA)

The Overlapping Layers of Blood Safety - I Donor Eligibility –Potential donors are provided educational materials to permit self deferral. Specific questions ask about their health, medical history, and other risk factors Testing for Communicable Diseases –Required: HIV, HBV, HCV, HTLV, syphilis –Voluntary: WNV, T. Cruzi, CMV Donor Deferral Registries –Blood establishments must keep current a list of individuals who have been deferred as blood or plasma donors

The Overlapping Layers of Blood Safety - II Quarantining of Unsuitable Blood –Blood products are quarantined until the products have been thoroughly tested and the donation records have been verified Investigation of Problems –Blood establishments must investigate any breaches of these safeguards and correct all system deficiencies Pathogen Reduction –Plasma derivatives undergo viral inactivation procedures

CBER Initiative: Blood Safety Team CBER established a Blood Safety Team in July 2006 Goals –To formalize Center operating procedures –To establish roles and responsibilities in the management of blood safety issues –To enhance internal and external communications

Blood Safety Team Major objectives: –To improve CBER responses to blood safety issues through defined cross Office collaboration creating increased sensitivity to safety signals –To improve the value of safety information and broaden public and regulated industry access to the information –To improve the processing of blood safety information through establishment of a forum for review and evaluation permitting discussions in a non-crisis mode and facilitating anticipation of events –To enhance external outreach, evaluation and risk communication

Center for Biologics Evaluation and Research: Offices with BST Members

Activities of the Blood Safety Team Coordinates investigations of potential shortages of blood and blood products –Due to manufacturing changes Investigation of impact of manufacturing changes Impact of potential recalls on public health –Due to reports of adverse events Investigation of adverse events –Due to reports of reduced stability Investigation of potential responses Seeks regulatory pathways to avert shortages

Activities of the Blood Safety Team Reviews Annual Fatality Reports from Whole Blood and Source Plasma Establishments (21 CFR [b]) and (21 CFR ) –Provides oversight for the annual report –Reviews communication opportunities Seeks potential etiologies –Donors: identify risk factors for fatalities –Recipients: improve understanding of adverse outcomes Investigates potential mitigating strategies

Activities of the Blood Safety Team Reviews Biologic Product Deviation Reports (BPDRs) and potential enhancements to reduce reporting burdens –Provides oversight for the annual report –Reviews the benefit of continued implementation of post donation information (PDI) Tattoos Donor history of cancer

Activities of the Blood Safety Team Evaluates manufacturing issues and potential safety impacts –Effect of breaches in cGMPs Bioburden excursions Impact on safety, purity, and potency Investigates approaches to threats to the blood supply –Reviews existing scientific information and supports public workshops

Activities of the Blood Safety Team Investigates impact of outbreaks of transfusion transmissible diseases on potential blood donors –e.g. Endoscopy related Implements a rapid response to urgent safety events –Investigates the impact of adulterated pharmaceutical ingredients On injection biologics Devices used to screen donors and to diagnose viral diseases

Ongoing BST Challenges Development and formalization of best cross Office approaches to key safety areas: –BPDRs: seeks ways to increase value to FDA and regulated industry –Emerging Infectious Diseases (EIDs): explores improvements in informatics –Data mining: use of advanced algorithms to detect safety signals –Need for denominators: investigates role of hospital based transfusionists to improve databases

CBER’s Blood Safety Team Summary Functions as a coordinated, agile, inter-Office team that evaluates, processes, investigates and responds to a variety of blood safety issues Plays an important role in external outreach and risk communication